Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 2 selected

Type

Guidance programme 11 selected

Guidance programme

Showing 201 to 250 of 571

TitleReference numberPublishedLast updated
Roxadustat for treating symptomatic anaemia in chronic kidney diseaseTA807
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDsTA803
Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglyceridesTA805
Belimumab for treating lupus nephritis (terminated appraisal)TA806
Fenfluramine for treating seizures associated with Dravet syndromeTA808
Setmelanotide for treating obesity caused by LEPR or POMC deficiencyHST21
Social, emotional and mental wellbeing in primary and secondary educationNG223
Teduglutide for treating short bowel syndromeTA804
Type 2 diabetes in adults: managementNG28
Depression in adults: treatment and managementNG222
Faricimab for treating diabetic macular oedemaTA799
Faricimab for treating wet age-related macular degenerationTA800
Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancerTA801
Cemiplimab for treating advanced cutaneous squamous cell carcinomaTA802
Multiple sclerosis in adults: managementNG220
Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiationTA798
Reducing sexually transmitted infectionsNG221
Venetoclax for treating chronic lymphocytic leukaemiaTA796
Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal)TA797
Preterm labour and birthNG25
Gout: diagnosis and managementNG219
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal)TA793
Diroximel fumarate for treating relapsing–remitting multiple sclerosisTA794
Ibrutinib for treating Waldenstrom's macroglobulinaemiaTA795
Filgotinib for treating moderately to severely active ulcerative colitisTA792
Social work with adults experiencing complex needsNG216
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal)TA790
Romosozumab for treating severe osteoporosisTA791
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterationsTA789
Vaccine uptake in the general populationNG218
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapyTA788
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and overHST20
Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapiesTA786
Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitableTA787
Elosulfase alfa for treating mucopolysaccharidosis type 4AHST19
Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adultsNG215
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancerTA784
Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal)TA785
Stroke and transient ischaemic attack in over 16s: diagnosis and initial managementNG128
Daratumumab monotherapy for treating relapsed and refractory multiple myelomaTA783
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancerTA781
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal)TA782
Atidarsagene autotemcel for treating metachromatic leukodystrophyHST18
Nivolumab with ipilimumab for untreated advanced renal cell carcinomaTA780
Integrated health and social care for people experiencing homelessnessNG214
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiencyTA779
Otitis media (acute): antimicrobial prescribingNG91
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoeaTA777
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuriaTA778
Empagliflozin for treating chronic heart failure with reduced ejection fractionTA773

Results per page

  1. 10
  2. 25
  3. 50
  4. All